RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
Regeneron Pharmaceuticals, Inc. REGN announced that the blockbuster asthma drug Dupixent (dupilumab) has been recommended by ...
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback